Fig. 6From: Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST RegistryComparison of treatment outcomes of vD2T RA by treatment types. Change in CDAI and HAQ-DI over the course of a year was compared using panel data analysis and IPTW among vD2T RA. TNFi is treated as a reference. *p < 0.05. vD2T RA, very difficult-to-treat rheumatoid arthritis; CDAI, Clinical Disease Activity Index; HAQ-DI, Health Assessment Questionnaire Disability Index; IPTW, propensity-based inverse-probability treatment weighted; TNFi, tumour necrosis factor inhibitor; IL-6Ri, interleukin-6 receptor inhibitor; CTLA4-Ig, cytotoxic T-lymphocyte-associated antigen-4 immunoglobulin; JAKi, Janus kinase inhibitorBack to article page